BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

Benzinga05-20

BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide (commonly...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636860229?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/19/Cancer---Heart-Shape-To-Represent-Medica.jpeg","is_english":true,"pubTime":"2026-05-20 06:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636860229","market":"us","top_or_hot":-1,"title":"BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models","media":"Benzinga","content":"<div>\n<p>BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide (commonly...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-20 06:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide (commonly...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDX","symbol_name":"Simplify High Yield ETF","start_time":0,"source_url":"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models","article_id":"2636860229","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/19/Cancer---Heart-Shape-To-Represent-Medica.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636860229","pubTimestamp":1779229680,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide -resistant model.In the threeorthotopic cell-derived xenograft  studies,significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels.In these models,mice treated with TMZ also showed significantly decreased tumor volume and survival benefit.Most notably, inthe subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect.The finding highlights the potential of GLIX1 to address the significant unmet needs of patients suffering from glioblastoma, an aggressive form of cancer.In April, BioLineRx initiated a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma.BLRX Price Action: BioLine Rx shar","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDX":"Simplify High Yield ETF"},"translate_title":"BioLineRx药物在脑肿瘤动物模型中显示抗肿瘤活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDX":1},"content_text":"BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide (commonly used chemotherapy)-resistant model.\nIn the three orthotopic cell-derived xenograft (CDX) studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels.\nIn these models, mice treated with TMZ also showed significantly decreased tumor volume and survival benefit.\nMost notably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect.\nThe finding highlights the potential of GLIX1 to address the significant unmet needs of patients suffering from glioblastoma, an aggressive form of cancer.\nIn April, BioLineRx initiated a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma.\n“GLIX1 has a very compelling profile supporting this Phase 1/2a study and, to that end, we look forward to initial data in the first half of 2027,”  stated Philip Serlin, CEO of BioLineRx.\nBLRX Price Action: BioLine Rx shares were down 5.90% during regular trading and down 2.28% in after-hours trading on Tuesday, last trading at $2.57, according to Benzinga Pro data.\nOver the past month, BLRX has gained about 13.7% versus a 3.5% rise in the S&P 500 and is down roughly 1% year-to-date compared to the index’s 7.0% gain.\nPhoto via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636860229","isCrawlerRequest":true}